Member Info for B2HS2L

Dear Ms Cowling

I would like to discuss the content of the AGM July 2019 presentation please:

https://novacyt.com/wp-content/uploads/2019/07/Novacyt-AGM-Presentation-July-2019-FINAL.pdf

Page 9 displays:

Novacyt Operations - Major OEM relationships, Examples: Bio-Rad, Thermo, Biomerieux.

Page 4 displays logo's for Danaher, Biomerieux, Bio-Rad, HOLOGIC, Qiagen and Becton Dickinson at the bottom of the page.

Could you please advise what JV's or projects or partnerships allow Novacyt to list these companies as partners please.
Any information you can provide would be very helpful.

Response:

Thank you for your interest in Novacyt S.A.

Due to the large amount of interest in the company at this time, we cannot respond to individual shareholder queries. Please see our website on www.novacyt.com for further information about the company. Any price sensitive information will be released via RNS in the usual way.

+++++

I recently researched the NCYT AIM Admissions document -

https://novacyt.com/wp-content/uploads/2017/10/Admission-Document-Novacyt-18-October-2017.pdf

I was looking to explain mention of partnerships in the AGM July 2019 presentation.

The NCYT AIM Admissions document mentions other parts of Novacyt, (Lab21 and the now sold NOVAprep)

The references to partnerships and logo's that appear in the AGM July 2019 presentation,
are partly explained by the below extracts of the October 2017 AIM Admissions document:

Page 17:
Lab21’s primary growth focus is the launch of complementary products into current markets as
well as adding new territories such as Brazil and the US. A significant portion of the Lab21
business has historically been tender driven from NGOs, for developing markets, an area that is
currently seeing significant recovery. In addition, Lab21 has a successful history of developing
major B2B partnerships with companies such as Becton, Dickinson and Company, Beckman
Coulter, The Danaher Corporation, Bio-Rad Laboratories, Inc. and will continue to focus on
developing such relationships to the benefit of the Group as a whole.

Page 20:
By using the Group’s existing partnership expertise and experience, additional sales channels are
being targeted in H2 2017; for instance an initial strong pipeline of B2B deals has been developed.
In the opinion of the Directors, there are considerable growth opportunities in working with other
large molecular manufacturers who have publicly stated their intentions to outsource the
development and manufacture of molecular assay content to third parties

Page 22:
Growth strategy

This page has more information as to why Novacyt has connections with large Pharma.

++++

I have posted this before, but while its quiet, and we still cannot confirm anything about US partnerships, I thought I would
post these findings.

These COPD results (which are excellent) are only half what we are looking for.

It is what option(s) the company now takes, based on these results:

1 Acquires approvals
2 Agrees distribution partner
3 Agrees buyout
4 Raises funds for whatever reason

One or many of the above are the next part of todays story, so I am holding (as ever).

That's where further shareholder value lies.

RM - keep chatting to the FDA, after all there is an election to be won here soon..

just my 2c

04.09.20

http://www.nationalhealthexecutive.com/Robot-News/nhs-lighthouse-lab-loughborough-capacity

Apologies if posted already.

With news of Covid stocks elsewhere today, we should be pleased that NCYT sp is pretty much unaffected.
This stock is definitely in sticky fingers, and will remain so until AGM.

6th Resolution:
"The Meeting resolves that:
- the maximum purchase price per share (excluding fees) is set at 12 euros; and
- the maximum amount of funds used for the implementation of this share buyback programme may not
exceed 200,000 euros."

This could be taken that the board can foresee a time when shares are worth at or above 12 Euros, at which point the number of shares you could buy with 200,000 Euros, (16666),would be insufficient to do a lot with.

Well we better hurry and adopt this, because we will be through 12 Euros pretty sharp when the company reveals the missing numbers in the RNS's lately..

02.09.2020 - BioWorld MedTech
FDA eyes self-administered testing for COVID-19 antigen tests

https://www.bioworld.com/articles/497329-fda-eyes-self-administered-testing-for-covid-19-antigen-tests

Interesting insights here, apologies if posted before.

Hi Bramley, here's my 2cents of feelings feedback you requested -

Whilst I am really pleased about the Winterplex development, I feel lukewarm about the Antibody test.
Trying to develop one is a waste of time IMO:
a) because a successful test is not easily achieved.
b) because development of this test would not be cheap, and I would not want profits ploughed back into developing this test.
c) If the Govnt has requested an Antibody test, I hope are we spending Govnt money on developing it, as there are already so many others to choose from, (Risk management).
That would mean though that we have fewer scientists for other projects.

We currently attract a low p/e because it is difficult to see what products are going to be the longer term
cash cows, (apart from Winterplex!).
Covid-19 might only be a force to be reckoned with until a successful vaccine is available in quantity.
This might never happen, or it might happen next year, but the Winterplex sales figures - whenever we get them, - will trigger a much more applicable p/e value.

I think we will be pleasantly surprised by the income from Covid H-T tests, - not sure we have seen a PHE contract though.
We know we are supplying but to Cambridge or is it all Lighthouse labs?

I am not bothered about the low sp. Things will re-rate whenever we are given the numbers.
If that is a not in the near future I shall wait, it fits in with my investment strategy.

I can't understand why the care homes have been neglected to the extant they have by govnt.
Families will blame the govnt for deaths of some relatives resident in care homes, and that will be reflected at the ballot box, even if it is > 4 years away.

Genesig Plex kit which test's for Flu A ,Flu B + RSV:

Thanks for the heads up EXMEX, I was not aware of this test.
Didn't see any mention of CE label in the handbook, so not sure why.
Adding a two gene covid19 test to this product would mean the purchaser would probably not see much change from £20 a test, (a bargain for 100 tests and not the normal 96 in one kit!).
Lets see at what price Shaun P is willing to place this product into his calculations, but we will not know for quite a while what sales are like, (as GM intends).
I always thought Winterplex would make a big difference to Winter sales, but probably the test will make good money all year round, Winter in Northern Hemisphere, and Winter in Southern hemisphere.
Thanks again Exmex - good spot.

https://www.genesig.com/assets/files/genesigplex_flua_m1__flub_rsv_spp_kit_handbook.pdf
https://www.genesig.com/assets/files/Path_SARS_CoV_2_Winterplex_IFU_Issue_100.pdf

I have not seen a price quoted for Winterplex, but it strikes me that further to yesterdays discussion about the deliberate lack of numbers in RNS's, the following might be true.

"Launch of respiratory test panel - New test differentiates COVID-19 from common winter diseases

Paris, France and Camberley, UK - 27 August 2020 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces the launch of its CE-Mark approved polymerase chain reaction (PCR) respiratory test panel, Winterplex™."

..."The test panel is designed to be used on any open PCR platform, including the Company's rapid, portable q32 instrument. The Company is using its existing manufacturing capacity to produce the test panel and believes it can meet the expected global demand for the product. The test panel is expected to drive significant incremental revenue for the Company."

If GM is true to form and the test panel succeeds in driving significant incremental revenue, and the company cannot supply orders from existing manufacturing capacity, then there will not be an update should any of the present partners start manufacturing the test panel. However if a new partner were contracted, I would think this would be RNS'd, as that would mean an increase in test manufacturing capacity.

My money is on Primerdesign being swamped.

With GM unwilling to put numbers in an RNS, I think he would make do with the original (RNS'd) statement, even if subsequently the agreement were expanded.
RNSing an expansion would give the opposition more information.

Numbers are what GM does not want to provide, the omissions from RNS's is unmistakable.
I can only think that if there are interested parties mulling over a bid for NCYT, then numbers will be provided to such parties after an NDA is signed.
Meanwhile GM wants to keep the opposition guessing, until he must provide numbers to shareholders.

++++

"Department of Health and Social Care contract to support the NHS
On 27 April 2020, Novacyt signed a supply contract with the UK Department of Health and Social Care (DHSC) for its COVID-19 test. Under the terms of the agreement, Novacyt will supply its COVID-19 test to the DHSC for an initial term of six months, starting from 4 May 2020. Novacyt has initially committed to supply 288,000 per week to the NHS, with the option to expand the agreement."

Quickdraw:
"There was a big Randox social care hole which I'll now assume Novacyt and others weren't able to fill. Now we see their is a PHE hospital shortage which is Primerdesigns core stomping ground."

Another way of looking at the present situation might be:

Hanc*ck has been saying this week that there are new tests which aren't quite ready yet, and simultaneously there are PHE hospital and testing centre shortages, necessitating long journeys to get tested. One conclusion to draw might be that the Govnt is not ordering sufficient tests in the expectation that these new tests will be approved (and importantly be available) shortly.
If the developers / manufacturers of these tests have not said 'Approved & Available shortly' to the likes of Hanc*ck and Johnson, then the govnt is playing a dangerous game, which might backfire if the number of tests required increases sharply soon.
++++
We have provided the Winterplex test in response to a Govnt requirement (with as yet no competing product choice available), so I am making the assumption that a contract will be signed soon. (definitely RNS-able).

Emmystar -

"I can’t understand why there isn’t a huge surge for the SP in France, after all, this is what they were asking for"?

France has been using 2 gene tests since the start of pandemic, and our 1 gene target test has been available but not available for reimbersement.
Primerdesign are just another late to the party 2 gene test provider.
2 things might change the situation:
1 An increase in the testing requirement will aid sales.
2 Lack of stock for users because of difficulties in supply from present test provider ( hard to come by reagents) et al.
Both of the above will aid sales in the near future, but at present, we are just another late to the party test provider.

Vive la.... - Oh just show me the money!!!

I think that is the case for Avacta licensing it's LFD to whomever.
If this happened, some of those LFD manufacturers will take longer than others to start producing.
I assume WHO would have an order to fill, but who would help them out when so busy mending their own economy is a quandary.

PAHOO - OK, Understood.
My point was that we should not take for granted that foreign LFD manufacturing facilities will be available to satisfy any order we give them.

Hi PAHOO,

"This could happen in other countries as well".

How many countries have LFT manufacturing facilities inside their boundaries?
G10 - Belgium, Canada, France, Germany, Italy, Japan, the Netherlands, Sweden, Switzerland, the United Kingdom, and the United States.
(I know that makes 11).

However at a guess I would treble this number, - 33 is my best guess.
So 33 governments are going to be unhappy to see foreign orders produced in their factories, as they will probably want the factory owners to produce for the home market.

Every nation that can produce LFT's for itself has the potential to request a license from Avacta (or whoever).
All other nations don't have that facility.

If you have LFD producing facilities, you have a chance to get your economy out of jail.

Vaccines are for those who HOPE it is not too difficult to develop a successful product.
Everybody else knows they will need to keep testing the population in an effort to get their economy up and running again.

Debtfree, I take that to mean Avacta, BBI and Cytiva.
He knows a lot more than he can say IMO, and fails to deliver convincing replies because he keeps checking that he is not giving anything away by uttering the next sentence.

Why is it that when Matt Hanc*ck is trying to develop sentences in response to a question, you get the feeling he was briefed on the subject half an hour ago, and he is trying desperately hard to remember what he read?

Perhaps more succinctly -
Not likely to be limited by approvals then.